調査レポートカテゴリー： MarketsandMarkets, 世界, 医療/バイオ

RSV Diagnostics Market by Product (Kits and Assays, Instruments), Method (Rapid Antigen Detection Test (Immunofluorescence Assay, ELISA), Molecular Diagnostic), End User (Hospitals & Clinics, Clinical Laboratories, Homecare) - Global Forecast to 2022

RSV診断の世界市場予測（～2022年）：キット、アッセイ、装置、方法、エンドユーザー

◆タイトル：RSV Diagnostics Market by Product (Kits and Assays, Instruments), Method (Rapid Antigen Detection Test (Immunofluorescence Assay, ELISA), Molecular Diagnostic), End User (Hospitals & Clinics, Clinical Laboratories, Homecare) - Global Forecast to 2022
◆商品コード：MAM-MD-6013
◆調査・発行会社：MarketsandMarkets
◆発行日：2018年2月16日
◆ページ数：115
◆レポート形式：PDF / 英語
◆納品方法：Eメール（受注後24時間以内）
◆調査対象地域：グローバル
◆産業分野：医療機器
◆販売価格オプション（消費税別）
Single User（1名利用）USD4,950 ⇒換算￥554,400見積依頼/購入/質問フォーム
Multi User (Five User)USD6,650 ⇒換算￥744,800見積依頼/購入/質問フォーム
Corporate License (全社内共有可)USD8,150 ⇒換算￥912,800見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※商品の納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。（振込先：三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社）
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※ご購入後、レポートに記載の英語表現や単語の意味に関しましては無料でお答えいたします。（但し、対応範囲は弊社で判断）
※弊社H&Iグローバルリサーチ株式会社はMarketsandMarketsの日本における正規販売代理店です。

 【レポートの概要】

MarketsandMarketsが発行した当調査レポートでは、RSV診断の世界市場について調査・分析し、エグゼクティブサマリー、市場インサイト、市場概観/市場動向、市場シェア分析、製品別分析、方式別分析、需要先別分析、地域別分析、RSV診断の世界市場規模及び予測、市場動向、競争状況、関連企業分析などの情報をお届けいたします。

“The global RSV diagnostics market projected to grow at a CAGR of 10.1% during the forecast period”The RSV diagnostics market is expected to reach USD 929.2 million by 2022 from USD 574.3 million in 2017, at a CAGR of 10.1%. Factors driving the growth of this market include rising burden of RSV infections, growing demand for molecular diagnostic tests for the diagnosis of RSV infections, increasing adoption of point-of-care testing for RSV diagnosis and increasing approval of RSV diagnostic kits and assays. On the other hand, the development of RSV vaccine is expected to emerge as a biggest threat which would alter the market growth in the coming years.
“Kits and Assays are estimated to grow at the highest CAGR during the forecast period”
The products market is further segmented into kits and assays, instruments, and other products. The kits and assays segment is expected to account for the largest share and grow at the highest CAGR during the forecast period. Factors driving the growth of this segment include the increasing infection of RSV in newborn infants and young children and growing demand for kits and assays for RSV diagnosis
“The molecular diagnostics segment is estimated to grow at the highest CAGR during the forecast period”
The method market is further segmented into Rapid Antigen Detection Tests, molecular diagnostics, and others methods. The molecular diagnostics segment is expected to account for the largest share of the global RSV diagnostics market in 2017. Market growth can largely be attributed to factors such as the increasing demand for molecular diagnostic testing for RSV diagnosis.
“Asia Pacific is estimated to grow at the highest CAGR during the study period”
Geographically, the RSV diagnostics market is dominated by North America, followed by Europe in 2017. Asia Pacific is estimated to grow at the fastest rate, due to increasing infectious disease burden such as RSV infection, increasing demand for RSV disease diagnosis, and increasing healthcare expenditure in APAC countries.
The primary interviews conducted for this report can be categorized as follows:
• By Company Type: Tier 1–43%, Tier 2–35%, Tier 3–22%
• By Designation: C level–62%, Director level–21%, Others–17%
• By Region: North America–32%, Europe–27%, Asia Pacific–22%, Rest of World –19%

The key players in the RSV diagnostics market include bioMérieux (France), Becton Dickinson (US), Abbott (US), Roche (Switzerland), Danaher (US), Thermo Fisher (US), Luminex (US), BioCartis (Belgium), Hologic (US), and Fast Track Diagnostics (Luxembourg).

Research Coverage:
The report analyses the RSV diagnostics market by product, method, end user, and region. Apart from a comprehensive geographic product analysis and market sizing, the report also provides a competitive landscape that covers growth strategies adopted by industry players over the last three years. In addition, the company profiles include the product portfolios, developments, and strategies adopted by prominent market players to maintain and increase their shares in the market. Market research data, current market size, and forecast of the future trends will help key market players and new entrants make the necessary decisions regarding product offerings, geographic focus, change in strategic approach, and levels of output in order to remain successful.
Key Benefits of Buying the Report:
This report will enable both established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn will help firms garner greater market shares. Firms purchasing the report can use one or a combination of the below mentioned five strategies for strengthening their market shares.
The report provides insights on the following pointers:
• Market Penetration: Comprehensive information on the product portfolios of the top players in the RSV diagnostics market.
• Product Development/Innovation: Detailed insights on upcoming technologies, R&D activities, and product launches in the RSV diagnostics market.
• Competitive Assessment: In-depth assessment of the market strategies, geographic and business segments, and product portfolios of the leading players in the RSV diagnostics market.
• Market Development: Comprehensive information about emerging markets. This report analyzes the market for various tissue diagnostics products and services across geographies.
• Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the RSV diagnostics market.

【レポートの目次】

TABLE OF CONTENTS

1 INTRODUCTION 11
1.1 OBJECTIVES OF THE STUDY 11
1.2 MARKET DEFINITION 11
1.3 SCOPE OF THE STUDY 12
1.3.1 YEARS CONSIDERED FOR THE STUDY 12
1.3.2 CURRENCY 13
1.4 LIMITATIONS 13
1.5 STAKEHOLDERS 13
2 RESEARCH METHODOLOGY 14
2.1 RESEARCH DATA 14
2.1.1 SECONDARY DATA 15
2.1.1.1 Key secondary sources 15
2.1.2 PRIMARY DATA 15
2.1.2.1 Breakdown of Primary Interviews, by Company Type, Designation, and Region 16
2.1.3 KEY DATA FROM PRIMARY SOURCES 16
2.2 MARKET SIZE ESTIMATION 17
2.2.1 BOTTOM-UP APPROACH 17
2.2.2 TOP-DOWN APPROACH 18
2.3 MARKET BREAKDOWN & DATA TRIANGULATION 19
2.4 ASSUMPTIONS FOR THE STUDY 20
3 EXECUTIVE SUMMARY 21
4 PREMIUM INSIGHTS 24
4.1 ATTRACTIVE OPPORTUNITIES IN THE RSV DIAGNOSTICS MARKET 24
4.2 GEOGRAPHIC ANALYSIS: RSV DIAGNOSTICS MARKET, BY PRODUCT & REGION (2017) 25
4.3 RSV DIAGNOSTICS MARKET, BY END USERS, 2017–2022 26
4.4 GEOGRAPHICAL SNAPSHOT OF THE RSV DIAGNOSTICS MARKET 26
5 MARKET OVERVIEW 27
5.1 INTRODUCTION 27
5.2 MARKET DYNAMICS 27
5.2.1 DRIVERS 28
5.2.1.1 Increasing burden of RSV infections 28
5.2.1.2 Growing demand for point-of-care molecular diagnostic tests for the diagnosis of RSV infections 29
5.2.1.2.1 Increasing adoption of molecular diagnostics over immunoassays 29
5.2.1.3 Increasing approval of RSV diagnostic kits and assays 30
5.2.2 RESTRAINTS 30
5.2.2.1 Low detection limits of immunoassays 30
5.2.3 OPPORTUNITIES 30
5.2.3.1 Technological advancements in diagnostic methods 30
5.2.4 THREATS 31
5.2.4.1 Development of RSV vaccines 31
6 RSV DIAGNOSTICS MARKET, BY PRODUCT 32
6.1 INTRODUCTION 33
6.2 KITS AND ASSAYS 34
6.3 INSTRUMENTS 35
6.4 OTHER PRODUCTS 37
7 RSV DIAGNOSTICS MARKET, BY METHOD 39
7.1 INTRODUCTION 40
7.2 MOLECULAR DIAGNOSTICS 41
7.3 RAPID ANTIGEN DETECTION TESTS 42
7.3.1 ENZYME-LINKED IMMUNOSORBENT ASSAYS 44
7.3.2 IMMUNOFLUORESCENCE ASSAYS 45
7.3.3 OTHER RAPID ANTIGEN DETECTION TESTS 47
7.3.3.1 Chromatographic immunoassays 48
7.3.3.2 Optical immunoassays 50
7.4 OTHER METHODS 51
8 RSV DIAGNOSTICS MARKET, BY END USER 53
8.1 INTRODUCTION 54
8.2 HOSPITALS AND CLINICS 55
8.3 CLINICAL LABORATORIES 56
8.4 HOME CARE 57
9 RSV DIAGNOSTICS MARKET, BY REGION 59
9.1 INTRODUCTION 60
9.2 NORTH AMERICA 61
9.2.1 US 64
9.2.2 CANADA 66
9.3 EUROPE 67
9.3.1 GERMANY 70
9.3.2 UK 71
9.3.3 FRANCE 73
9.3.4 REST OF EUROPE 74
 
9.4 APAC 76
9.5 ROW 79
10 COMPETITIVE LANDSCAPE 81
10.1 INTRODUCTION 81
10.2 MARKET OVERVIEW 81
10.3 MARKET SHARE ANALYSIS, 2016 82
10.4 COMPETITIVE SCENARIO 83
10.4.1 PRODUCT LAUNCHES AND APPROVALS 83
10.4.2 ACQUISITIONS 83
10.4.3 AGREEMENTS AND COLLABORATIONS 84
10.4.4 EXPANSIONS 84
11 COMPANY PROFILES 85
Business Overview, Products Offered, Recent Developments, MNM View
11.1 BIOMÉRIEUX 85
11.2 BECTON, DICKINSON AND COMPANY (BD) 87
11.3 ABBOTT 89
11.4 ROCHE 91
11.5 DANAHER 93
11.6 THERMO FISHER 95
11.7 BIOCARTIS 97
11.8 LUMINEX 99
11.9 HOLOGIC 101
11.10 FAST TRACK DIAGNOSTICS 103
*Details might not be captured in case of unlisted companies.
12 APPENDIX 104
12.1 INDUSTRY INSIGHTS 104
12.2 DISCUSSION GUIDE 105
12.3 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 108
12.4 INTRODUCING RT: REAL-TIME MARKET INTELLIGENCE 110
12.5 AVAILABLE CUSTOMIZATIONS 111
12.6 RELATED REPORTS 112
12.7 AUTHOR DETAILS 113

LIST OF TABLES

TABLE 1 CURRENT STATUS OF RSV VACCINES 31
TABLE 2 RSV DIAGNOSTICS MARKET, BY PRODUCT, 2015–2022 (USD MILLION) 33
TABLE 3 RSV DIAGNOSTICS MARKET FOR KITS AND ASSAYS, BY REGION,
2015–2022 (USD MILLION) 34
TABLE 4 NORTH AMERICA: RSV DIAGNOSTICS MARKET FOR KITS AND ASSAYS,
BY COUNTRY, 2015–2022 (USD MILLION) 34
TABLE 5 EUROPE: RSV DIAGNOSTICS MARKET FOR KITS AND ASSAYS, BY COUNTRY,
2015–2022 (USD MILLION) 35
TABLE 6 RSV DIAGNOSTICS MARKET FOR INSTRUMENTS, BY REGION,
2015–2022 (USD MILLION) 36
TABLE 7 NORTH AMERICA: RSV DIAGNOSTICS MARKET FOR INSTRUMENTS, BY COUNTRY, 2015–2022 (USD MILLION) 36
TABLE 8 EUROPE: RSV DIAGNOSTICS MARKET FOR INSTRUMENTS, BY COUNTRY,
2015–2022 (USD MILLION) 36
TABLE 9 RSV DIAGNOSTICS MARKET FOR OTHER PRODUCTS, BY REGION,
2015–2022 (USD MILLION) 37
TABLE 10 NORTH AMERICA: RSV DIAGNOSTICS MARKET FOR OTHER PRODUCTS,
BY COUNTRY, 2015–2022 (USD MILLION) 37
TABLE 11 EUROPE: RSV DIAGNOSTICS MARKET FOR OTHER PRODUCTS, BY COUNTRY, 2015–2022 (USD MILLION) 38
TABLE 12 RSV DIAGNOSTICS MARKET, BY METHOD, 2015–2022 (USD MILLION) 40
TABLE 13 MOLECULAR DIAGNOSTICS MARKET, BY REGION, 2015–2022 (USD MILLION) 41
TABLE 14 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY COUNTRY,
2015–2022 (USD MILLION) 41
TABLE 15 EUROPE: MOLECULAR DIAGNOSTIC MARKET, BY COUNTRY,
2015–2022 (USD MILLION) 42
TABLE 16 RAPID ANTIGEN DETECTION TESTS MARKET, BY TYPE, 2015–2022 (USD MILLION) 42
TABLE 17 RAPID ANTIGEN DETECTION TESTS MARKET, BY REGION,
2015–2022 (USD MILLION) 43
TABLE 18 NORTH AMERICA: RAPID ANTIGEN DETECTION TESTS MARKET, BY COUNTRY, 2015–2022 (USD MILLION) 43
TABLE 19 EUROPE: RAPID ANTIGEN DETECTION TESTS MARKET, BY COUNTRY,
2015–2022 (USD MILLION) 43
TABLE 20 RAPID ANTIGEN DETECTION TESTS MARKET FOR ENZYME-LINKED IMMUNOSORBENT ASSAYS, BY REGION, 2015–2022 (USD MILLION) 44
TABLE 21 NORTH AMERICA: RAPID ANTIGEN DETECTION TESTS MARKET FOR ENZYME-LINKED IMMUNOSORBENT ASSAYS, BY COUNTRY, 2015–2022 (USD MILLION) 44
TABLE 22 EUROPE: RAPID ANTIGEN DETECTION TESTS MARKET FOR ENZYME-LINKED IMMUNOSORBENT ASSAYS, BY COUNTRY, 2015–2022 (USD MILLION) 45
TABLE 23 RAPID ANTIGEN DETECTION TESTS MARKET FOR IMMUNOFLUORESCENCE ASSAYS, BY REGION, 2015–2022 (USD MILLION) 45
TABLE 24 NORTH AMERICA: RAPID ANTIGEN DETECTION TESTS MARKET FOR IMMUNOFLUORESCENCE ASSAYS, BY COUNTRY, 2015–2022 (USD MILLION) 46
TABLE 25 EUROPE: RAPID ANTIGEN DETECTION TESTS MARKET FOR IMMUNOFLUORESCENCE ASSAYS, BY COUNTRY, 2015–2022 (USD MILLION) 46
TABLE 26 OTHER RAPID ANTIGEN DETECTION TESTS MARKET, BY TYPE,
2015–2022 (USD MILLION) 47
TABLE 27 OTHER RAPID ANTIGEN DETECTION TESTS MARKET, BY REGION,
2015–2022 (USD MILLION) 47
TABLE 28 NORTH AMERICA: OTHER RAPID ANTIGEN DETECTION TESTS MARKET,
BY COUNTRY, 2015–2022 (USD MILLION) 48
TABLE 29 EUROPE: OTHER RAPID ANTIGEN DETECTION TESTS MARKET, BY COUNTRY,
2015–2022 (USD MILLION) 48
TABLE 30 RAPID ANTIGEN DETECTION TESTS MARKET FOR CHROMATOGRAPHIC IMMUNOASSAYS, BY REGION, 2015–2022 (USD MILLION) 49
TABLE 31 NORTH AMERICA: RAPID ANTIGEN DETECTION TESTS MARKET FOR CHROMATOGRAPHIC IMMUNOASSAYS, BY COUNTRY, 2015–2022 (USD MILLION) 49
TABLE 32 EUROPE: RAPID ANTIGEN DETECTION TESTS MARKET FOR CHROMATOGRAPHIC IMMUNOASSAYS, BY COUNTRY, 2015–2022 (USD MILLION) 49
TABLE 33 RAPID ANTIGEN DETECTION TESTS MARKET FOR OPTICAL IMMUNOASSAYS,
BY REGION, 2015–2022 (USD MILLION) 50
TABLE 34 NORTH AMERICA: RAPID ANTIGEN DETECTION TESTS MARKET FOR OPTICAL IMMUNOASSAYS, BY COUNTRY, 2015–2022 (USD MILLION) 50
TABLE 35 EUROPE: RAPID ANTIGEN DETECTION TESTS MARKET FOR OPTICAL IMMUNOASSAYS, BY COUNTRY, 2015–2022 (USD MILLION) 51
TABLE 36 OTHER METHODS MARKET FOR RSV DIAGNOSTICS, BY REGION,
2015–2022 (USD MILLION) 51
TABLE 37 NORTH AMERICA: OTHER METHODS MARKET FOR RSV DIAGNOSTICS,
BY COUNTRY, 2015–2022 (USD MILLION) 52
TABLE 38 EUROPE: OTHER METHODS MARKET FOR RSV DIAGNOSTICS,
BY COUNTRY/REGION, 2015–2022 (USD MILLION) 52
TABLE 39 RSV DIAGNOSTICS MARKET, BY END USER, 2015–2022 (USD MILLION) 54
TABLE 40 RSV DIAGNOSIS MARKET FOR HOSPITALS AND CLINICS, BY REGION,
2015–2022 (USD MILLION) 55
TABLE 41 NORTH AMERICA: RSV DIAGNOSIS MARKET FOR HOSPITALS AND CLINICS,
BY COUNTRY, 2015–2022 (USD MILLION) 55
TABLE 42 EUROPE: RSV DIAGNOSIS MARKET FOR HOSPITALS AND CLINICS, BY REGION, 2015–2022 (USD MILLION) 56
TABLE 43 RSV DIAGNOSIS MARKET FOR CLINICAL LABORATORIES, BY REGION,
2015–2022 (USD MILLION) 56
TABLE 44 NORTH AMERICA: RSV DIAGNOSIS MARKET FOR CLINICAL LABORATORIES,
BY COUNTRY, 2015–2022 (USD MILLION) 57
TABLE 45 EUROPE: RSV DIAGNOSIS MARKET FOR CLINICAL LABORATORIES, BY REGION, 2015–2022 (USD MILLION) 57
TABLE 46 RSV DIAGNOSIS MARKET FOR HOME CARE, BY REGION,
2015–2022 (USD MILLION) 58
TABLE 47 NORTH AMERICA: RSV DIAGNOSTICS MARKET FOR HOME CARE, BY COUNTRY, 2015–2022 (USD MILLION) 58
TABLE 48 EUROPE: RSV DIAGNOSTICS MARKET FOR HOME CARE, BY REGION,
2015–2022 (USD MILLION) 58
TABLE 49 RSV DIAGNOSTICS MARKET, BY REGION, 2015–2022 (USD MILLION) 60
TABLE 50 NORTH AMERICA: RSV DIAGNOSTICS MARKET, BY COUNTRY,
2015–2022 (USD MILLION) 63
TABLE 51 NORTH AMERICA: RSV DIAGNOSTICS MARKET, BY PRODUCT,
2015–2022 (USD MILLION) 63
TABLE 52 NORTH AMERICA: RSV DIAGNOSTICS MARKET, BY METHOD,
2015-2022 (USD MILLION) 63
TABLE 53 NORTH AMERICA: RSV DIAGNOSTICS MARKET, BY END USER,
2015–2022 (USD MILLION) 64
TABLE 54 US: RSV DIAGNOSTICS MARKET, BY PRODUCT, 2015–2022 (USD MILLION) 65
TABLE 55 US: RSV DIAGNOSTICS MARKET, BY METHOD, 2015-2022 (USD MILLION) 65
TABLE 56 US: RSV DIAGNOSTICS MARKET, BY END USER, 2015–2022 (USD MILLION) 65
TABLE 57 CANADA: RSV DIAGNOSTICS MARKET, BY PRODUCT, 2015–2022 (USD MILLION) 66
TABLE 58 CANADA: RSV DIAGNOSTICS MARKET, BY METHOD, 2015-2022 (USD MILLION) 66
TABLE 59 CANADA: RSV DIAGNOSTICS MARKET, BY END USER, 2015–2022 (USD MILLION) 67
TABLE 60 EUROPE: RSV DIAGNOSTICS MARKET, BY COUNTRY, 2015–2022 (USD MILLION) 69
TABLE 61 EUROPE: RSV DIAGNOSTICS MARKET, BY PRODUCT, 2015–2022 (USD MILLION) 69
TABLE 62 EUROPE: RSV DIAGNOSTICS MARKET, BY METHOD, 2015-2022 (USD MILLION) 69
TABLE 63 EUROPE: RSV DIAGNOSTICS MARKET, BY END USER, 2015–2022 (USD MILLION) 70
TABLE 64 GERMANY: RSV DIAGNOSTICS MARKET, BY PRODUCT, 2015–2022 (USD MILLION) 70
TABLE 65 GERMANY: RSV DIAGNOSTICS MARKET, BY METHOD, 2015-2022 (USD MILLION) 71
TABLE 66 GERMANY: RSV DIAGNOSTICS MARKET, BY END USER, 2015–2022 (USD MILLION) 71
TABLE 67 UK: RSV DIAGNOSTICS MARKET, BY PRODUCT, 2015–2022 (USD MILLION) 72
TABLE 68 UK: RSV DIAGNOSTICS MARKET, BY METHOD, 2015-2022 (USD MILLION) 72
TABLE 69 UK: RSV DIAGNOSTICS MARKET, BY END USER, 2015–2022 (USD MILLION) 72
TABLE 70 FRANCE: RSV DIAGNOSTICS MARKET, BY PRODUCT, 2015–2022 (USD MILLION) 73
TABLE 71 FRANCE: RSV DIAGNOSTICS MARKET, BY METHOD, 2015-2022 (USD MILLION) 73
TABLE 72 FRANCE: RSV DIAGNOSTICS MARKET, BY END USER, 2015–2022 (USD MILLION) 74
TABLE 73 ROE: RSV DIAGNOSTICS MARKET, BY PRODUCT, 2015–2022 (USD MILLION) 75
TABLE 74 ROE: RSV DIAGNOSTICS MARKET, BY METHOD, 2015-2022 (USD MILLION) 75
TABLE 75 ROE: RSV DIAGNOSTICS MARKET, BY END USER, 2015–2022 (USD MILLION) 75
TABLE 76 APAC: RSV DIAGNOSTICS MARKET, BY PRODUCT, 2015–2022 (USD MILLION) 78
TABLE 77 APAC: RSV DIAGNOSTICS MARKET, BY METHOD, 2015-2022 (USD MILLION) 78
TABLE 78 APAC: RSV DIAGNOSTICS MARKET, BY END USER, 2015–2022 (USD MILLION) 78
TABLE 79 ROW: RSV DIAGNOSTICS MARKET, BY PRODUCT, 2015–2022 (USD MILLION) 80
TABLE 80 ROW: RSV DIAGNOSTICS MARKET, BY METHOD, 2015-2022 (USD MILLION) 80
TABLE 81 ROW: RSV DIAGNOSTICS MARKET, BY END USER, 2015–2022 (USD MILLION) 80
TABLE 82 SHARE OF COMPANIES IN THE RSV DIAGNOSTICS MARKET (2016) 82
TABLE 83 PRODUCT APPROVALS AND LAUNCHES, 2014–2018 83
TABLE 84 ACQUISITIONS, 2014–2018 83
TABLE 85 AGREEMENTS AND COLLABORATIONS, 2014–2018 84
TABLE 86 EXPANSIONS, 2014–2018 84


LIST OF FIGURES

FIGURE 1 RESEARCH DESIGN 14
FIGURE 2 BOTTOM-UP APPROACH 17
FIGURE 3 TOP-DOWN APPROACH 18
FIGURE 4 DATA TRIANGULATION METHODOLOGY 19
FIGURE 5 RSV DIAGNOSTICS MARKET, BY PRODUCT, 2017 VS. 2022 (USD BILLION) 21
FIGURE 6 RSV DIAGNOSTICS MARKET, BY METHOD, 2017 VS. 2022 (USD BILLION) 22
FIGURE 7 RSV DIAGNOSTICS MARKET, BY END USER, 2017 VS. 2022 (USD BILLION) 22
FIGURE 8 RSV DIAGNOSTICS MARKET, BY REGION, 2017 VS. 2022 (USD BILLION) 23
FIGURE 9 INCREASING INCIDENCES OF RSV INFECTION AND INCREASING ADOPTION
OF MOLECULAR DIAGNOSTICS ARE DRIVING THE GROWTH OF THE RSV
DIAGNOSTICS MARKET 24
FIGURE 10 MOLECULAR DIAGNOSTICS IS ESTIMATED TO COMMAND THE LARGEST
MARKET SHARE IN 2017 25
FIGURE 11 HOSPITALS AND CLINICS TO GROW AT THE HIGHEST RATE DURING
THE FORECAST PERIOD 26
FIGURE 12 APAC TO REGISTER THE HIGHEST CAGR BETWEEN 2017 & 2022 26
FIGURE 13 RSV DIAGNOSTICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES,
AND THREATS 27
FIGURE 14 KITS AND ASSAYS SEGMENT WILL CONTINUE TO DOMINATE THE
RSV DIAGNOSTICS MARKET IN 2022 33
FIGURE 15 MOLECULAR DIAGNOSTICS SEGMENT WILL CONTINUE TO DOMINATE
THE RSV DIAGNOSTICS MARKET IN 2022 40
FIGURE 16 HOSPITALS AND CLINICS SEGMENT WILL CONTINUE TO DOMINATE
THE RSV DIAGNOSTICS MARKET IN 2022 54
FIGURE 17 APAC TO REGISTER THE HIGHEST GROWTH IN THE RSV DIAGNOSTICS
MARKET DURING THE FORECAST PERIOD 60
FIGURE 18 NORTH AMERICA: RSV DIAGNOSTICS MARKET SNAPSHOT 62
FIGURE 19 EUROPE: RSV DIAGNOSTICS MARKET SNAPSHOT 68
FIGURE 20 APAC: RSV DIAGNOSTICS MARKET SNAPSHOT 77
FIGURE 21 ROW: RSV DIAGNOSTICS MARKET SNAPSHOT 79
FIGURE 22 PRODUCT LAUNCHES, THE MOST ADOPTED GROWTH STRATEGY FROM
2014 TO 2018 81
FIGURE 23 BIOMÉRIEUX: COMPANY SNAPSHOT (2016) 85
FIGURE 24 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2016) 87
FIGURE 25 ABBOTT: COMPANY SNAPSHOT 89
FIGURE 26 ROCHE: COMPANY SNAPSHOT (2016) 91
FIGURE 27 DANAHER: COMPANY SNAPSHOT 93
FIGURE 28 THERMO FISHER SCIENTIFIC: COMPANY SNAPSHOT 95
FIGURE 29 BIOCARTIS: COMPANY SNAPSHOT (2016) 97
FIGURE 30 LUMINEX: COMPANY SNAPSHOT (2016) 99
FIGURE 31 HOLOGIC: COMPANY SNAPSHOT (2016) 101


【レポートのキーワード】

RSV検査キット、RSV検査アッセイ、RSV検査装置

★調査レポート[RSV診断の世界市場予測（～2022年）：キット、アッセイ、装置、方法、エンドユーザー] ( RSV Diagnostics Market by Product (Kits and Assays, Instruments), Method (Rapid Antigen Detection Test (Immunofluorescence Assay, ELISA), Molecular Diagnostic), End User (Hospitals & Clinics, Clinical Laboratories, Homecare) - Global Forecast to 2022 / MAM-MD-6013) 販売に関する免責事項
[RSV診断の世界市場予測（～2022年）：キット、アッセイ、装置、方法、エンドユーザー] ( RSV Diagnostics Market by Product (Kits and Assays, Instruments), Method (Rapid Antigen Detection Test (Immunofluorescence Assay, ELISA), Molecular Diagnostic), End User (Hospitals & Clinics, Clinical Laboratories, Homecare) - Global Forecast to 2022 / MAM-MD-6013) についてEメールでお問い合わせ
◆関連調査資料◆
  • 感染症診断の世界市場予測（～2022年）：製品・サービス、疾患種類、技術、エンドユーザー
    MAM-MD-3088 / MarketsandMarkets / 2018年4月16日 / MarketsandMarketsが発行した当調査レポートでは、感染症診断の世界市場について調査・分析し、エグゼクティブサマリー、市場インサイト、市場概観/市場動向、製品・サービス別分析、疾患種類別分析、技術別分析、エンドユーザー別分析、感染症診断の世界市場規模及び予測、市場動向、競争状況、関連企業分析などの情報をお届けいたします。...“The global infectious disease diagnostics market is projected to grow at a CAGR of 5.6%.”The global infectious disease diagnostics market is expected to reach USD 19.35 billion by 2022 from USD 14.73 billion in 2017, at a CAGR of 5.6%. Growth in this market can primarily be attributed to factors such as increasing global prevalence of infectious diseases, shift in focus from centralized laboratories to decentralized point-of-care testing, and growth in funding for research on infectious disease diagnostics. However, inadequate reimbursement and rising healthcare cost limiting usage of novel diagnostic technologies are expected to restrain the growth of this market...

    • ◆H&Iグローバルリサーチ株式会社のお客様（例）◆